The oncology market, in terms of revenue, was valued at USD 93.60 Bn in 2020 and is expected to reach US$ 127.52 Bn by 2030. Some of the primary players of global oncology market are Roche, Novartis, Celgene, Bristol Myers Squibb, Johnson & Johnson, Pfizer, Eli Lilly, AstraZeneca, AbbVie, Incyte, Eisai, Sanofi and Merck & Co. among others.

Oncology is a study of Cancer. The illness is described by irregular cell multiplication, which is trailed by local tissue invasion. At an advanced stage of the disease, the cancer cells migrate to different parts of the body. Cancer is a hereditarily determined illness, with iterative transformations giving selective advantages to the cells with regards to the particular tissue site, trailed by clonal expansion.

Download Sample PDF For Business Information:

Global Oncology Market (USD Billion), By Region

Cancer is foreseen to become increasingly prevalent because of aging population and rising levels of obesity in the developed world. Besides, the advancement and approval of more targeted oncology treatments are foreseen to decrease toxicity and increase chemotherapy use in elderly patients. Targeted treatment organization will upturn the overall survival.

In 2012, there were 32.6 million individuals living with cancer within five years of diagnosis. These are generally incurable once they advance to the phase where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of numerous kinds, at different illness stages. In a typical course of treatment for cancer, numerous chemotherapy compounds are regulated consecutively in combination regimens, as an adjunct to surgery and radiation treatment. Chemotherapy drugs are cytotoxic to partitioning cells, implying that they follow up on both healthy and malignant tissues and are fairly lethal.

Various common etiologic variables have been emphatically portrayed as raising the risk of developing cancer, including age, interminable irritation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases exceedingly in patients beyond 65 years old. Populations in developed countries are anticipated to become progressively aged and demonstrate rising obesity incidence, which will drive both cancer predominance and revenue growth for its treatments.

Oncology Market, By Cancer Type

On the basis of cancer type, the global market is segmented into blood cancer, breast cancer, prostate cancer, skin cancer, and lung cancer among others. Among these, blood cancer segment represented a major share of the global oncology market in 2016 and is anticipated to hold the largest share of the overall market throughout the forecast period. The development of blood cancer segment is significant because of the high cost of the medications used to treat blood cancer. The prevalence of blood cancer is less in well-established countries, and also diagnosis rate is over 90%. This results in most of the individuals diagnosed striving for complete treatment to cure it. Because of the high disposable incomes of customers in developed nations, costly medication treatment of blood cancer is affordable in these regions.

Oncology Market, By Region

North America dominates the market for cancer drugs as the region houses organizations occupied with the advancement in cancer drugs. Correspondingly, the disposable revenues of consumers and health insurance cover for severe sickness in North America are high, which expands the affordability of tumor treatment. Furthermore, US Food and Drug Administration (USFDA) has undertaken activities to support the development of the market by giving a pre-market approval to the medications, which are in the clinical stage; in this way, accelerating the clinical development.

Countless patents in North America demonstrate a substantial investment in R&D from multinational organizations and also research organizations. Europe is the second largest revenue generating region for the oncology market and is relied upon to develop at a CAGR of 7.9% amid the forecast time frame. In U.S. and Europe, a majority of the multinational players has focused on the development of biologics or immunotherapeutic inferable from its high adequacy and target particular action. The research for cancer drugs in Asia-Pacific and LAMEA is rising with the concentration towards the improvement of biosimilars. The predominance of high growth in developing nations, renders these districts as promising areas to direct clinical trials. In addition, the cost of clinical research is low in these region, because of the availability of an enormous population base and good government arrangements adding to the oncology/malignancy drugs showcase development in the developing nations.

Oncology by Cancer Market research added by Absolute Markets Insights, offers a comprehensive analysis of the growth trends prevailing in the global business arena. This report also provides definitive data regarding the market, size, marketing aspects, and revenue forecast of the industry. In addition, the study explicitly highlights the competitive status of major players in the projection schedule while focusing on their portfolio and regional expansion efforts.

The Global Oncology by Cancer Market Analysis to 2030 is a specialized and in-depth study of the Technology, Media, and Telecommunications industry, with an emphasis especially on the analysis of global market trends. The report aims to provide an overview of the enterprise content delivery networks and enterprise streaming software market with detailed market segmentation by component, type of deployment, industry vertical, and geography. The global market for enterprise content delivery networks and enterprise streaming software is expected to witness high growth during the forecast period.

Financial performance:
The overall turnover of the companies / segments for the years 2021, 2020 and 2019 is provided in the sub-heading “Financial performance” (listed companies) with the analysis and explanation of the increase or decrease. decrease in these due to factors such as mergers and acquisitions, profit or loss of any strategic business unit (SBU) and others.

Strategic initiatives:
Information relating to new product launches, strategic collaboration, mergers and acquisitions, regulatory approval and other company developments in the market is covered in the strategic initiatives section.

Oncology by Cancer Market: Regional analysis includes:
- Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)
- Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
- North America (United States, Mexico and Canada.)
- South America (Brazil etc.)
- The Middle East and Africa (GCC countries and Egypt.)

This research provides detailed information on the major factors influencing the Oncology by Cancer market growth on a global and regional level (drivers, restraints, opportunities and challenges), forecast of market size, in terms of value, market share by region and segment; regional market positions; growth opportunities by segment and by country, strengths and weaknesses, brand portfolio; Marketing and distribution strategies; challenges and threats of current competition and prospects; Key Company Profiles, SWOTs and Growth Strategies.

The Oncology by Cancer market research covers a comprehensive analysis of the following data:
• Historical and future growth of the Global Oncology by Cancer market.
• Segmentation of enterprise content delivery network and enterprise streaming software market to highlight the growth prospects and trends impacting these segments.
• Change the consumption behavior of customers in different regions.
• Regional analysis on the basis of market share, growth prospects and key countries.
• Agreements, product launches, acquisitions and R&D projects of various players in the enterprise content delivery networks and enterprise streaming software market.

Get More Information :

Contact Us:
Company: Absolute Markets Insights
Email Id:
Phone: IN +91-740-024-2424, US +1-510-420-1213
Contact Name: Shreyas Tanna